HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranitidine Recalls Begin In Europe As Regulators Take Action

Executive Summary

OTC products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.

You may also be interested in...



EMA Stands By Suspension Of Ranitidine

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

EMA Stands By Suspension Of Ranitidine In EU After Re-Examination

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

EMA Advocates Suspension Of All Ranitidine Drugs In EU

Concerns over the presence of a probable human carcinogen will likely see marketing of all ranitidine-containing drugs suspended across the European Union.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel